Compara mètodes

	Assaig de la membrana corioal·lantoica (CAM)	Electrospinning	MTT/MTS Assay
Camp	Biomaterials	Biomaterials	Biomaterials
Família	Process / pipeline	Process / pipeline	Process / pipeline
Any d'origen	1974	1934	1983
Autor original	Judah Folkman	Anton Formhals	Tatsuro Mosmann
Tipus	Developmental biology assay	Fiber fabrication process	Colorimetric assay
Font seminal	Folkman, J. (1974). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186.	Formhals, A. (1934). Process and apparatus for preparing artificial threads. U.S. Patent 1,975,504.	Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1-2), 55-63.
Àlies	chick embryo chorioallantoic membrane, angiogenesis assay, CAM angiogenesis model	electrospun fiber production, electrostatic fiber spinning	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, tetrazolium assay, mitochondrial activity assay
Relacionats	4	3	4
Resum	The chorioallantoic membrane (CAM) assay is a well-established in vivo model for studying angiogenesis (new blood vessel formation) and evaluating the pro- or anti-angiogenic properties of biomaterials, drugs, and bioactive molecules. Developed by Judah Folkman in the 1970s, the assay uses the highly vascularized CAM of developing chick embryos as a platform for implanting test materials and observing vascular response. The CAM provides a transparent, immunologically naive microenvironment with rapid and reproducible neovascularization, making it ideal for screening angiogenic potential and assessing biomaterial biocompatibility.	Electrospinning is an electrostatic fiber fabrication process that uses a high electric field to draw polymer solutions or melts into nanoscale fibers. Developed by Anton Formhals in the 1930s and refined by researchers including Darrell Reneker in the 1990s, the technique has become foundational to biomaterials engineering, enabling the creation of porous scaffolds for tissue engineering and drug delivery systems.	The MTT assay, introduced by Tatsuro Mosmann in 1983, is a colorimetric method for quantifying cell viability and proliferation by measuring mitochondrial metabolic activity. The method detects the conversion of the water-soluble tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by active mitochondria, producing an insoluble purple formazan precipitate proportional to the number of viable cells. The related MTS assay, which does not require solubilization, offers improved kinetics and is now widely adopted in both academic research and pharmaceutical development.